LimmaTech Biologics

Vaccine development company working to halt AMR and STI infections.

Invested: 2023

Modality: Vaccine

Website: https: lmtbio.com

Read Post

Memo Therapeutics

Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.

Invested: 2022

Modality: Therapeutic

Read Post

Curevo Vaccine

Next-generation subunit vaccines, initially targeting varicella and shingles.

Invested: 2022

Modality: Vaccine

Read Post

Antiva Biosciences

Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.

Invested: 2021

Modality: Therapeutic

Website: antivabio.com

Read Post

Pulmocide

Novel therapies for patients suffering from serious acute and chronic respiratory diseases.

Invested: 2021

Modality: Inhaled Therapeutic

Website: pulmocide.com

Read Post

Excision BioTherapeutics

CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.

Invested: 2021

Modality: Therapeutic

Website: excision.bio

Read Post

Frontier Nutrition

Fortified snacks to address maternal and childhood malnutrition in Bangladesh.

Invested: 2020

Modality: Lipid-Based Nutritional Supplements (LNS)

Read Post

VitriVax

Thermostability and pulsatile dosing technology for vaccines and other sensitive biologics.

Invested: 2020

Modality: Vaccine

Website: vitrivaxbio.com

Read Post

MinervaX

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns.

Invested: 2020

Modality: Vaccine

Website: minervax.com

Read Post

Evofem

Woman-controlled, non-hormonal contraceptive.

Invested: 2020

Modality: Contraceptive

Website: evofem.com

Read Post

Univercells

Univercells uses advanced manufacturing technologies to make "Biologics for all."

Invested: 2020

Modality: Process Innovation

Website: univercells.com

Read Post

YS Biopharma

Yisheng is scaling up undersupplied global health vaccines and developing innovative new biologics.

Invested: 2020

Modality: Vaccine

Read Post

ChromaCode

ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.

Invested: 2020

Modality: Platform

Website: chromacode.com

Read Post

54gene

54gene is using African genetic data to drive discoveries in drug and vaccine development.

Invested: 2020

Modality: Platform

Website: 54gene.com

Read Post

Codagenix

Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.

Invested: 2020

Modality: Platform

Website: codagenix.com

Read Post

AN2 Therapeutics

AN2 is developing novel, broad-spectrum therapeutics for infectious diseases.

Invested: 2019

Modality: Small Molecule

Read Post

Acquired by Merck in 2020

Themis

Themis is developing novel vaccines for high burden infectious diseases and oncology applications.

Invested: 2019

Modality: Vaccine

Website: themisbio.com

Read Post

InDevR

InDevR is developing advanced characterization assays for biologics.

Invested: 2019

Modality: Process Innovation

Website: indevr.com

Read Post

X-Vax

X-Vax is developing a vaccine to beat herpes.

Invested: 2019

Modality: Vaccine

Website: x-vax.com

Read Post